Using gold nanoprobes to unlock your genetic profile

A fast and cost-effective genetic test to determine the correct dosage of blood thinning drugs for the treatment of stroke, heart problems and deep vein thrombosis has been developed by researchers at the Institute of Bioengineering ...

Actavis buying Warner Chilcott in $8.5B deal

Actavis is buying Warner Chilcott in an all-stock deal valued at about $8.5 billion that would create the third-biggest specialty pharmaceutical company in the U.S. market.

page 1 from 2